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Background: Studying within-host genetic diversity of Mycobacterium tuberculosis (Mtb) in patients during
treatment may identify adaptations to antibiotic and immune pressure. Understanding the significance of
genetic heteroresistance, and more specifically heterozygous resistance-associated variants (RAVs), is clini-
cally important given increasing use of rapid molecular tests and whole genome sequencing (WGS).
Methods:We analyse data from six studies in KwaZulu-Natal, South Africa. Most patients (>75%) had baseline
rifampicin resistance. Sputum was collected for culture at baseline and at between two and nine intervals
until month six. Positive cultures underwent WGS. Mixed infections and reinfections were excluded from
analysis.
Findings: Baseline Mtb overall genetic diversity (at treatment initiation or major change to regimen) was
associated with cavitary disease, not taking antiretroviral therapy if HIV infected, infection with lineage 2
strains and absence of second-line drug resistance on univariate analyses. Baseline genetic diversity was not
associated with six-month outcome. Genetic diversity increased from baseline to weeks one and two before
returning to previous levels. Baseline genetic heteroresistance was most common for bedaquiline (6/10
[60%] of isolates with RAVs) and fluoroquinolones (9/62 [13%]). Most patients with heterozygous RAVs on
WGS with sequential isolates available demonstrated RAV persistence or fixation (17/20, 85%). New RAVs
emerged in 9/286 (3%) patients during treatment. We could detect low-frequency RAVs preceding emergent
resistance in only one case, although validation of deep sequencing to detect rare variants is required.
Interpretation: In this study of single-strain Mtb infections, baseline within-host bacterial genetic diversity
did not predict outcome but may reveal adaptations to host and drug pressures. Predicting emergent resis-
tance from low-frequency RAVs requires further work to separate transient from consequential mutations.
Funding:Wellcome Trust, NIH/NIAID
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license.
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The Mycobacterium tuberculosis complex (MTBC), consisting of
seven human-adapted lineages as well as several animal-adapted
strains which may also cause human disease, is a major human path-
ogen. The most prominent species in the complex, Mycobacteriumtuberculosis (Mtb), represents the infectious agent causing most
deaths worldwide [1]. Mtb has traditionally been viewed as a geneti-
cally homogenous bacterium that has evolved into a specialised
human pathogen with a lower mutation rate than most other bacte-
ria and no accessory genome or potential for horizontal gene transfer
[2]. More recent work has identified significant within-host Mtb
genetic diversity which may result from mixed infection with multi-
ple strains or within-host microevolution of a single infecting strain
[3]. Such genetic diversity is not surprising given that Mtb infections
typically last months to years and within-host bacterial populations
Research in context
Evidence before this study
High-throughput sequencing can identify genetic differences
among bacteria infecting an individual patient (referred to as
within-host genetic diversity). Greater Mycobacterium tubercu-
losis (Mtb) genetic diversity has been seen in tuberculosis (TB)
patients who are failing treatment and in genes responsible for
encoding bacterial cell wall lipids and for the response to
antibiotics.
The clinical implications of low-frequency resistance muta-
tions are unclear. Engelthaler et al. identified low-frequency
mutations pre-dating phenotypic resistance in around 40% of
patients who acquired resistance to second-line drugs, while
modelling by Vargas et al. suggested that resistance mutations
at >19% frequency often increase to fixation but those at lower
frequencies tend to disappear in sequential sampling. However,
the dynamics of low-frequency resistance mutations have not
been studied prospectively.
Added value of this study
We found that baseline overall genetic diversity was associated
on univariate analysis with presence of lung cavities, not taking
antiretroviral therapy (if HIV co-infected), infection with line-
age 2 Mtb strains and absence of second-line drug resistance.
We identified a transient increase in genetic diversity in the ini-
tial weeks following treatment initiation or a major change to
regimen that was caused by genes from a variety of functional
categories. Heteroresistance conferred by resistance-associated
variants at frequencies >30% persisted or became fixed in all
but one case. Low-frequency resistance-associated variants at
<5% were not associated with the identification of emergent
resistance.
Implications of all the available evidence
Studying genes responsible for within-host pathogen genetic
diversity during treatment may help identify new mechanisms of
adaptation to drug and immune pressure. Our data were consis-
tent with work suggesting that low-frequency resistance-associ-
ated variants (e.g. <5%) are not clinically relevant while those at
higher frequency (e.g. >30%) are. Larger studies with frequent
sampling and clinical outcome data using a testing system vali-
dated to detect a range of allele mixtures are required to delineate
a clear minimum variant frequency threshold and inform roll-out
of molecular and sequencing technologies.
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to 50 consensus-level SNP differences having been reported to occur
over the duration of infection in patients with advanced disease
when sampling from multiple body sites [4]. While genetic diversity
arising from mixed infections has been associated with poor clinical
outcomes [5,6], the effect of within-host diversity of single strain
infections is undefined.
Within-host genetic diversity reflects the extent to which
genomes (in this case Mtb genomes originating from individual bac-
teria) within a population (comprising all bacteria in the cultured iso-
late) are genetically distinct. It can be measured by nucleotide
diversity (p), which is the mean number of nucleotide substitutions
per site between any two randomly selected DNA sequences in a pop-
ulation, and takes a value between 0 and 1 [7]. We refer to any site
carrying more than one allele as ‘heterozygous’, following standard
practice in the population genetics literature to define multi-allelic
loci, irrespective of ploidy [812].Understanding factors affecting within-host Mtb genetic diversity
may offer insights into mechanisms controlling bacterial replication
and evolution. Studying sequential isolates from individual patients
over the course of treatment could help identify signatures of bacte-
rial adaptation to drug treatment and the host immune environment.
Previous studies of within-host diversity have focused on reanalysis
of published sequences from patients who have failed treatment. One
detailed study of five patients revealed that overall Mtb genomic
diversity increased with disease severity and was particularly high in
pre-mortem isolates from two patients presumably due to high bac-
terial load [13]. The most diverse genes were those involved in pro-
duction of cell envelope lipids. No evidence for a decrease in diversity
during treatment or any effect of Mtb lineage or drug resistance pro-
file was found, and HIV statuses were not available for analysis. A
larger analysis of combined data from eight publicly available studies
reporting patients who failed treatment found that genes associated
with antibiotic resistance displayed highest diversity, while the
within-host diversity across remaining gene classes (essential, non-
essential, PE/PPE genes and antigen genes) seemed unaffected [14].
However, when reanalysing data collected by other groups, it may
be difficult to account for the role that pathogen culture and subse-
quent subculturing steps may have on genetic diversity through ran-
dom loss or selection of culture-adapted subpopulations. We and
others have shown that culture-independent sequencing of Mtb
directly from sputum identifies more genetic diversity than sequenc-
ing from culture [15,16], while other studies have shown subculture
can lead to loss of heterozygous resistance-associated variants
(RAVs) [17]. Furthermore, detailed analysis of low-frequency variants
can be affected by errors induced during PCR steps of genomic library
preparation [18] and incorrect mapping of contaminant DNA [19].
Mixed populations of wild-type alleles and RAVs confers hetero-
resistance, where populations of resistant and susceptible bacteria
co-exist within the same host. This may occur as the result of differ-
ential drug penetration to spatially and pathologically distinct lung
regions [20] leading in effect to monotherapy and subsequent resis-
tance acquisition or survival of susceptible bacteria. Such mixed pop-
ulations of wild type alleles and RAVs have been termed
macroheteroresistance when RAVs are present at 5% frequency, a
threshold above which they would be identified by most standard
WGS pipelines, and microheteroresistance when RAVs are at <5% fre-
quency [21]. Several case reports have identified heterozygous RAVs
(hetRAVs) that have increased in frequency over the course of treat-
ment [2224] leading to fixed resistance, including variants origi-
nally identified at <1% frequency [25], and genetic
microheteroresistance has been identified predating acquired pheno-
typic resistance [26]. However, due to high levels of turnover of low-
frequency variants, it may be difficult to predict which hetRAVs are
likely to persist or become fixed and which ones will disappear.
HetRAVs are likely to be variably identified by current diagnostics
[27,28] and so it may be difficult to predict whether such resistance
is taken into account when clinical drug treatment regimens were
designed for these patients.
The limit of detection for heterozygous variants depends on sev-
eral factors including the number of reads covering a site, the mini-
mum number of supporting reads required to call a variant and error
rates at each step of the sequencing pipeline. For example, in this
study where we have included sequences with a minimum 55x mean
genome coverage with four reads required to call a variant, the limit
of detection would be an allele frequency of 7%. We also use deep
sequencing to >3000x coverage, where using a minimum of 6 sup-
porting reads gives resolution to identify variants down to 0.2% fre-
quency. However, the important caveat to this is that as coverage
depth increases and the limit of detection decreases, the potential
false positive rate due to PCR or sequencing errors increases. Using a
base quality score of >30 (an error of 1 in 1000) and published DNA
polymerase error rates [29], a base error rate of 0.10.2% would be
Table 1
Description of cohort studies from which patients in this analysis were included. BL = baseline, W1 = week 1 etc., M1 = month 1 etc., EndTX = end of treatment, MDR = multidrug-
resistant TB, XDR = extensively drug-resistant TB. Isolates with minimum 55£ mean genome coverage were included in the analysis of heteroresistance and sequential genetic
diversity. Isolates with minimum 80£ mean genome coverage were included in the analysis of baseline genetic diversity. Number of patients with a baseline isolate are shown,
with the number of those who had at least one sequential isolate shown in brackets. ClinicalTrials.gov registration number for PRAXIS study shown.
Study number Study name Design Patients recruited Sputum collection timepoints Patients with baseline (and 1
sequential) isolates by minimum
coverage
55£ 80£
1 PRAXIS Aim 1
(NCT03162107)
Observational cohort
study
MDR / XDR
Starting bedaquiline
BL, M1, M2, M3, M4, M5, M6,
EndTX
57 (23) 49
2 PRAXIS Aim 2
(NCT03162107)
Randomised con-
trolled trial
MDR / XDR
Starting bedaquiline
BL, M2, M6, EndTX 35 (6) 38
3 CUBS (PZAP arm) Observational cohort
study
MDR
Treated with pyrazinamide
BL, W1, W2, W4, W6, M2, M3,
M4, M5, M6
79 (54) 72
4 REPORT-SA Observational cohort
study
DS BL, W1, W3, M2, M6 (EndTX) 66 (33) 67
5 Hlabisa DR-TB Observational cohort
study
MDR BL 113 (N/A) 108
6 CUBS (FIND arm) Observational cohort
study
MDR BL, M2, M6, EndTX 49 (2) 18
Total 399 (118) 352
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some genomic regions [30].
In this study we used prospectively enrolled patients with TB to
identify factors associated with within-host Mtb genetic diversity in
single strain infections and assess whether this type of genetic diver-
sity is associated with poor outcomes. We then investigated the out-
comes of genetic heteroresistance and whether presence of
microheteroresistance could predict the emergence of macroheter-
oresistance.
2. Methods
2.1. Patient recruitment
We analysed data from five observational cohort studies and a
randomised controlled trial in KwaZulu-Natal, South Africa, as
described in Table 1, conducted between 2016 and 2019. We selected
mostly cohorts that recruited patients with drug-resistant TB (DR-TB),
as these patients have previously experienced the worst outcomes and
most problems with acquired resistance, as well as one drug-suscepti-
ble cohort. Patients were recruited before or on the day of initiating
treatment or undergoing a major change in treatment due to a change
in drug resistance profile or clinical treatment failure. To be classified a
major change in treatment regimen, the patient had to be starting at
least two new drugs, be culture positive and have a previous regimen
that was likely to be ineffective based on drug susceptibility testing
(DST) results. At enrolment, all patients completed a study question-
naire and provided a sputum sample. Patients were reassessed at the
intervals described in Table 1 with a follow-up questionnaire and
repeat sputum sample (except in Hlabisa DR-TB cohort where follow-
up involved completion of clinical record forms only). All patients pro-
vided written informed consent to participate. All study protocols
were approved by the University of KwaZulu-Natal Biomedical
Research Ethics Committee. PRAXIS was also approved by Columbia
University Review Board and the Hlabisa DR-TB study by the London
School of Hygiene & Tropical Medicine Ethics Committee.
Every patient from these cohorts was included if they were
enrolled prior to February 2019 and were culture positive with a
baseline Mtb isolate with sufficient mean genome-wide coverage
depth for the proposed analysis: 80x for evaluation of baseline diver-
sity, 55x for evaluation of diversity and heteroresistance in sequential
isolates. Minimum coverage thresholds were chosen to maximise
sequencing coverage depth, and therefore ability to identify low level
variation, while ensuring that sufficient numbers of samples fulfilledthe criteria for inclusion. A lower threshold was used for the sequen-
tial analysis as some follow-up samples did not meet the minimum
80x coverage depth threshold. As described below, sequences for
diversity analyses were downsampled to a standard mean coverage,
while original coverage was used for heteroresistance. A list of iso-
lates included in each analysis and associated accession numbers is
available in the Supplementary Spreadsheet.
2.2. Microbiology
All sputum samples were decontaminated, homogenised and
inoculated into liquid mycobacterial growth indicator tube (MGIT)
and on Middlebrook 7H11 solid agar forMtb culture. Positive cultures
underwent phenotypic DST for first- and second-line drugs on 7H11
agar using the 1% agar proportion method [31]. The critical concen-
trations used are listed in the Supplementary Methods.
2.3. Genome sequencing
DNA was extracted for whole genome sequencing (WGS) from all
positive MGIT cultures by mechanical ribolysis before purification
with AMPure XP beads (Beckman Coulter, IN, USA) (full description
in Supplementary Methods). When MGIT cultures yielded insufficient
DNA for sequencing or were contaminated, DNA extraction from the
parallel 7H11 culture or a 7H9 subculture was attempted. Given that
multiple subculturing steps have been shown to reduce diversity, at
most a single subculture step was used if required. Sequencing librar-
ies were prepared with NEBNext Ultra II DNA (New England Biolabs,
MA, USA) according to the manufacturer’s instructions, with between
four and fourteen PCR cycles depending on input DNA concentration.
Batches of 48 multiplexed isolates were sequenced on a NextSeq 500
(Illumina, CA, USA) with 300-cycle paired end runs using a mid-out-
put kit.
Where emergent RAVs were identified by WGS, targeted deep
sequencing was performed retrospectively on stored surplus
extracted DNA from preceding isolates. A custom-designed SureSe-
lect bait set (Agilent, CA, USA) covering genes associated with drug
resistance comprising approximately 3% of the genome was designed
and used for target capture of Mtb DNA from drug resistance-associ-
ated genes (Supplementary Table 1). Overlapping 120 base pair RNA
baits were designed using SureDesign (Agilent) to cover the entire
positive strand of over 800 Mtb genomes downloaded from NCBI
Sequencing Read Archive selected to cover the global genetic diver-
sity ofMtb. Bait design is freely available from the authors on request.
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which is longer than the standard sequencing read of 150 base pairs.
Hybridisation and library preparation were performed with the Sure-
SelectXT Low Input kit (Agilent) protocol according to the manufac-
turer’s instructions, including 2023 PCR cycles depending on input
concentration. Genomic libraries were multiplexed with 96 isolates
sequenced on a NextSeq 500 (Illumina, CA, USA) 300-cycle paired
end run using a mid-output kit.
2.4. Bioinformatic analysis
Raw sequencing reads had adapters removed with Trim Galore
v0.3.7 [32] and were mapped to the H37Rv reference genome
(NC_000962.3) with BBMap v38.32 [33] with a 98% identity thresh-
old. Mapped reads were sorted and de-duplicated with Picard Tools
v2.20 [34] and mean genome coverage depth was checked with Qual-
imap v2.21 [35]. FreeBayes v1.3.1 [36] was used to call variants with a
specified minimum mapping quality 20 and base quality 30. For a
variant to be called, 4 supporting reads were required for WGS and
6 supporting reads for targeted deep sequencing, including at least
one on each strand with coverage 10. Variants were classed as het-
erozygous if present at <95% frequency or fixed if present at 95%
frequency. Variants falling within repetitive regions poorly resolved
by short read mapping (PE/PPE and esx genes and those categorised
as insertion sequences and phages [37]) were excluded from the
analysis.
Two steps were used in order to identify mixed infections. First,
isolates with evidence of heterozygous SNPs at established lineage-
specific sites [38] were classified as mixed infections. Then, to iden-
tify mixed infections of strains from the same sublineage (which
would share sublineage-specific SNPs), we used a previously
described method which identifies isolates with high numbers of het-
erozygous SNPs and then measures the degree of allele frequency
clustering to discriminate within-host evolution of a single strain
from infection with two genetically distinct strains [9].
The level of isolate contamination was estimated using Kraken2
[39] to classify the proportion of k-mers allocated to the genusMyco-
bacterium using the MiniKraken2 v2 database (updated 23/04/2019).
To prevent differences in coverage depth potentially affecting meas-
ures of p, aligned sequences were downsampled using Picard Tools
v2.20 [34] DownSampleSam. For baseline analysis, sequences were
downsampled to mean 80x coverage depth and for sequential analy-
sis to mean 55x coverage. Sequences were not downsampled for the
analysis of heteroresistance. Within-isolate p was calculated by an
in-house program that has been described previously [40] using base
counts extracted from mapped alignments by bam-readcount [41]
with mapping quality >20 and base quality >30. Diversity of individ-
ual genes was calculated using Popoolation v1.2 [42] with the follow-
ing parameters: pool size 500, minimum coverage 4, minimum count
2, minimum quality 30. For the comparison of diversity at the gene
level, coding genes were annotated with one of seven functional cate-
gories as described in Mycobrowser [37]. For comparability, we also
labelled each gene as antibiotic resistance (Rv0678, Rv1979c and rplC
were recategorised as antibiotic resistance genes), antigen, essential
or non-essential as described previously [14] (PE/PPE genes were
excluded from our analysis).
We first aimed to determine if the number of PCR cycles in library
preparation or proportion of reads assigned to Mycobacteria in the
isolate affected within-patient genetic diversity, as each PCR cycle
comes with a theoretical risk of introducing base errors. We also
investigated the possibility that contaminating reads erroneously
mapped toMycobacteriamay inflate the genetic diversity.
For identification of RAVs, we used a curated list of resistance-
conferring mutations adapted from published sources [43,44] as
listed in the Supplementary Methods. We supplemented these muta-
tions lists with more recent published data for new and repurposeddrugs [4548]. For mutations in the bedaquiline/clofazimine resis-
tance-associated gene Rv0678 and delamanid resistance-associated
genes fbiA/B/C, fgd1 and ddn, where a wide array of different muta-
tions leading to loss of function occur, we took a more sensitive
approach and manually evaluated all non-synonymous SNPs and
indels for potential to cause resistance. We assumed that all loss of
function mutations (frameshift or premature stop codons) to be
potentially causative of resistance, as well as any SNPs previously
reported to be associated with resistance.
2.5. Clinical assessment
Structured clinical record forms were completed at all visits by
dedicated research nurses. Responses were taken from patients ver-
bally as well as from clinic/hospital records. Chest radiography find-
ings were recorded as documented by the treating clinician. Six-
month outcome was assessed as favourable (alive, on treatment, Mtb
culture negative at months 5 and 6) or unfavourable (death, loss to
follow-up, culture positive at month 5 or 6).
2.6. Statistical analysis
Statistical analyses were performed using Stata/IC v15.1 (Stata-
Corp, TX, USA). Distributions of non-parametric data were compared
with Wilcoxon rank-sum test. Binary outcomes were assessed by
logistic regression and continuous variables with linear regression.
The Benjamini-Hochberg procedure was used to control for multiple
tests when evaluating change in median p between baseline and
sequential timepoints with Q (false positive rate) of 0.1, which should
yield less than one false positive test when performing seven tests.
3. Results
3.1. Patient selection and identification of mixed infection
A total of 399 from the 710 patients recruited into six different
studies described in Table 1 were included in this study. The most
common reason for exclusion was lack of a positive Mtb culture for
sequencing. Treatment data were available for 334/399 (84%)
patients and are described in the next paragraph. In some of these
334 cases there was discordance between the initial clinical resis-
tance profile upon which drug treatment decisions were based and
the study WGS profile: 2/66 (3%) patients initially diagnosed with
drug-susceptible TB (DS-TB) actually had multidrug-resistant TB
(MDR-TB) at baseline, and 25/268 (9%) patients treated for MDR-TB
did not have rifampicin resistance detected on WGS. This may have
been due previous mixed infection with other strains not found in
the study sample, false positive/negative DST results or lab error.
All patients with DS-TB were treated with the standard treatment
regimen (rifampicin, isoniazid, pyrazinamide and ethambutol). In
line with global developments, there were substantial changes in
DR-TB treatment regimens over the course of this study
(20162019). At the beginning of this period, long regimens
(20 months+) based on a fluoroquinolone and kanamycin were stan-
dard. For MDR-TB, these were progressively replaced with the short
(nine-month) regimen based on kanamycin and a fluoroquinolone,
and later bedaquiline and a fluoroquinolone. Pre-extensively/exten-
sively drug-resistant TB (pre-XDR/XDR-TB) treatment remained long
individualised regimens, although use of bedaquiline and linezolid
became more common. Among the 268 patients with DR-TB for
whom we have treatment data, all except three had been treated
with bedaquiline or kanamycin: 128 received bedaquiline, 118 kana-
mycin and 19 received both or switched from kanamycin to bedaqui-
line. All except two patients with DR-TB received a fluoroquinolone.
Full baseline treatment information in included in the Supplementary
Spreadsheet.
Table 2
Clinical and bacterial correlates of nucleotide diversity (p) in the 331 single strain
baseline isolates downsampled to 80x mean coverage, showing number in each cate-
gory, median p (£106) and interquartile range, and p-value (Wilcoxon rank sum,
except k-sample equality of medians where denoted by *).
Characteristic Number Median p £ 106 (IQR) p value
Patient factors
Age category
<25 32 0.995 (0.4901.54) 0.73*
2530 63 1.09 (0.6191.48)
3035 63 0.981 (0.6591.55)
3540 50 0.846 (0.4891.15)
4050 72 0.961 (0.6641.52)
50 45 0.863 (0.5781.23)
Missing 6
Sex
Male 188 0.969 (0.6401.55) 0.31
Female 137 0.944 (0.5631.39)
Missing 6
Previous TB
No 167 0.973 (0.6191.53) 0.50
Yes 155 0.916 (0.5781.41)
Missing 9
HIV status
Negative 60 1.02 (0.6781.48) 0.33
Positive 268 0.939 (0.5731.47)
Missing 3
CD4 count (if HIV positive)
<200 89 0.916 (0.5871.33) 0.41
200 106 0.831 (0.4981.30)
Missing 73
Taking ART (if HIV positive)
No 66 1.16 (0.7441.71) 0.010
Yes 176 0.837 (0.5621.34)
Missing 26
Cavitation on chest radiography
No 89 0.725 (0.4671.09) 0.017
Yes 26 1.05 (0.6681.59)
Missing 216
On TB treatment at enrolment
No 153 1.03 (0.6721.63) 0.049
Yes 170 0.847 (0.5631.36)
Missing 8
BACTERIAL FACTORS
Mtb Lineage
1 10 1.49 (1.142.10) Lineage 2 v 4
2 117 1.46 (1.021.93) <0.001
3 8 1.24 (1.091.62)
4 196 0.691 (0.4861.04)
Genetic drug resistance profile
DS 83 1.14 (0.6681.71) DS v MDR 0.22
MDR 179 1.03 (0.6511.51) DS v Pre-XDR/XDR <0.001
Pre-XDR/XDR 69 0.689 (0.4460.948) MDR v Pre-XDR/XDR <0.001
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coverage threshold of 80x included in the analysis of baseline isolates
(collected at initiation or major change to treatment). We excluded
21/352 isolates (6.0%) that we characterised as mixed infection, and
conducted detailed analyses on the remaining 331 single strain infec-
tions. We did not identify any patient or bacterial factors significantly
associated with likelihood of mixed infection (Supplementary Table
2). Patients were only included in the analysis of sequential isolates if
they had >1 successfully sequenced positive culture after excluding
isolates with evidence of reinfection or superinfection since baseline
(<15 SNP differences from baseline isolate) or mixed infection. There
were 348 individual isolates from 118 patients with >1 timepoint at
coverage above 55x included in the sequential analysis.
3.2. Whole genome nucleotide diversity at baseline
Among single strain infections, there was no difference in median p
when isolates were stratified by the number of PCR cycles (p = 0.72,
equality of medians test, Supplementary Figure 1). There was also no
evidence for an association between p and the proportion of reads
assigned to Mycobacteria (R-squared 0.6%, p = 0.16 for linear associa-
tion, Supplementary Figure 2), suggesting that high stringency map-
ping with BBMap adequately prevented mapping of contaminating
reads. Finally, we tested whether isolates grown on solid media or after
a single subculture in 7H9 were less diverse than those sequenced
from MGIT culture, and again found no evidence for a statistically sig-
nificant difference in p between groups (Supplementary Figure 3). We
therefore concluded that the number of PCR cycles, isolate contamina-
tion and culture media did not significantly impact on within-host
genetic diversity for the purposes of this study. As expected, mixed
infections had significantly higher median p than single strain infec-
tions (7.75£ 106 v 9.48£ 107, p<0.001, Wilcoxon rank-sum test).
As bacterial load was expected to affect p, we tested for associa-
tion with two measures of bacterial load: sputum smear grading and
time to positivity of the original MGIT isolate (TTP). Smear grading is
expected to increase and TTP to decrease with higher bacterial bur-
den. There was no linear trend between increasing smear grade and
p (R-squared 0.3%, p = 0.43, Supplementary Figure 4), and while there
was evidence for a linear trend of increase of pwith higher TTP (coef-
ficient 1.22 £ 108, p = 0.017, Supplementary Figure 5), it explained
only a small proportion of the variance (R-squared 1.8%).
To investigate how p varied in patients starting/changing TB
treatment, we tested its association with the following patient fac-
tors: age, sex, HIV status, CD4 count <200 (and taking antiretroviral
therapy (ART)), cavitation on chest radiography, previous TB infection
and if the patient was on TB treatment at the time of enrolment (for
example for DS-TB prior to detection of drug resistance) (Table 2).
We found that absence of cavitation on chest radiography (p = 0.017,
Wilcoxon rank-sum), taking ART (if HIV positive) (p = 0.017) and who
were taking TB treatment (p = 0.049) at the time of enrolment were
independently associated with a lower p on univariate analysis. In
addition to these patient factors, we also examined bacterial lineage
and drug resistance profile (Table 2). Lineages 2 and 4 are the major
groups circulating in South Africa [49] which was also the case in our
dataset. Patients infected with lineage 2 strains had greater p than
those with lineage 4 infections (p<0.001). While there was no differ-
ence in p between patients with genetically DS-TB and TB genetically
resistant to first line drugs (rifampicin/multidrug-resistant TB,
RR/MDR-TB), patients with genetic second-line drug resistance
(pre-XDR/XDR-TB) had lower p than patients with DS-TB (p<0.001)
and RR-TB (p<0.001).
3.3. Association between nucleotide diversity and outcome
We next tested if there was a correlation between baseline (initia-
tion or major change to treatment) p and six-month outcome. Six-month outcomes were available for 297/331 (89.7%) patients with
single strain infection, of whom 236/297 (79.5%) had a favourable
six-month outcome. Unfavourable outcomes were due to death (24/
297, 8.1%), loss to follow-up (20/297, 6.7%), and microbiological fail-
ure without acquired genetic resistance (11/297, 3.7%) or with
acquired genetic drug resistance (6/297, 2.0%). We found that male
sex, HIV coinfection and not taking ART therapy if HIV positive were
associated with higher risk of unfavourable outcome (Supplementary
Table 3). Interestingly, genetically MDR-TB infection was not associ-
ated with worse outcomes at month six than genetically DS-TB,
although pre-XDR/XDR-TB infection was on univariate analysis
(Table 2). Mixed infection, lineage, age, cavitation and previous TB
infection also did not affect outcome. On univariate analysis, p was
not associated with six-month outcome (Table 3). Not taking ART if
HIV positive, pre-XDR/XDR-TB and taking TB treatment at the time of
diagnosis (e.g. for DS-TB prior to an MDR-TB diagnosis) were consid-
ered as potential confounders and adjusted odds ratios were calcu-
lated. A final multivariate model was constructed including these
potential confounders for both all patients (not including ART as a
Table 3
Univariate and multivariate logistic regression analyses for the association between
baseline nucleotide diversity (p) and month six outcome.
Variable Odds ratio for unfavourable
outcome (95% confidence
intervals)
p-value
Univariate analysis:
Nucleotide diversity (p)
(n = 297)
0.84 (0.531.36) 0.4923
Controlling for confounding by each of:
Taking ART (if HIV positive)
(n = 225)
1.06 (0.651.75) 0.798
On TB treatment at enrolment
(n = 296)
0.80 (0.501.30) 0.381
Drug resistance profile
(n = 297)
1.07 (0.651.75) 0.798
Multivariate analysis (n = 296)
Nucleotide diversity (p) 0.92 (0.561.50) 0.739
On TB treatment at enrolment
Drug resistance profile (DS/
MDR vs Pre-XDR/XDR)
Multivariate analysis (HIV positive only, n = 224)
Nucleotide diversity (p) 1.08 (0.631.85) 0.774
Taking ART (if HIV positive)
On TB treatment at enrolment
Drug resistance profile (DS/
MDR vs Pre-XDR/XDR)
6 C. Nimmo et al. / EBioMedicine 55 (2020) 102747confounder) as well as HIV positive patients only (including ART as a
confounder), but neither demonstrated an association between base-
line p and six-month outcome (Table 3).
3.4. Dynamics of nucleotide diversity at the whole genome level during
treatment
For the analysis of sequential isolates, all sequences (including
baseline sequences) were downsampled to mean 55x genome-wide
coverage. There were 118 patients included in this analysis, of which
115 had baseline isolates that met inclusion criteria. Three patients
were excluded as they did not have a baseline sequence meeting cri-
teria. Median p in these 115 isolates was 8.67 £ 107, and not signifi-
cantly different (p = 0.104, Wilcoxon rank-sum test) to the value ofFig. 1. Box plot showing median and interquartile range of nucleotide diversity (p) in seque
isolates at each timepoint. Circles mark outlying values and all represent different patients, e
labelled. Bars indicate where p statistically significantly differs from baseline (Wilcoxon rank9.48 £ 107 from the 331 baseline isolates downsampled to 80x ana-
lysed above. When comparing median p amongst all isolates at each
timepoint, week 1 and 2 isolates showed an increase in p to
1.14 £ 106 and 1.15 £ 106 respectively (Fig. 1), while there was no
difference between baseline p and that at later timepoints. As this
could be due to patients with less diverse baseline sequences culture
converting rapidly, the analysis was repeated by including only
patients who had a positive culture after week 2 of treatment, which
yielded similar results (Supplementary Figure 6). The increase in p at
weeks one and two remained statistically significant after correcting
for multiple tests for both of these analyses. It is important to note
that 61/115 (53%) of these patients were receiving TB treatment at
the time of the baseline sample that was deemed to be ineffective
due to programmatically-identified drug resistance, as is commonly
the case for patients starting DR-TB treatment in South Africa. These
patients had generally been taking treatment for one or more months
and had by definition remained culture positive. However, it is possi-
ble that the changes in within-isolate diversity profiles for these
patients over time may be different to those who were completely
drug-naïve. When considering only the 54 patients who were not
taking TB treatment at the time of enrolment, there were no statisti-
cally significant differences in p during treatment (Supplementary
Figure 7).3.5. Individual gene-level nucleotide diversity
We then assessed within-isolate genetic diversity for all coding
genes at baseline (initiation or major change to treatment). In addi-
tion to functional categories, two additional redundant categories of
antibiotic resistance genes and antigen genes were generated as
described in the methods. There was no difference in mean p
between any gene or functional category in the 331 single strain
baseline isolates downsampled to 80x coverage (Table 4). The most
diverse coding genes at baseline are listed in Supplementary Table 4,
although many are not yet well described. In line with previous
results [15], Rv1319c, a putative adenylate cyclase responsible for
regulation of cellular metabolism was the gene displaying the highest
within-host genetic diversity.ntial isolates for timepoints where there were 5 isolates. Numbers indicate number of
xcept K0045 who was an outlier at baseline (month 0) and week 1 (month 0.25) and is
-sum test).
Table 4
Mean nucleotide diversity (p) and 95% confidence intervals (expressed at £ 106) in
baseline isolates by functional group and gene description.
Classification Baseline p (£ 106)
Mean Lower 95% CI Upper 95% CI
Functional groups
Cell wall and cell processes 3.05 2.69 3.40
Conserved hypotheticals 3.50 2.88 4.11
Information pathways 3.26 2.97 3.55
Intermediary metabolism and respiration 3.21 2.62 3.80
Lipid metabolism 3.37 2.75 3.98
Regulatory proteins 2.93 2.64 3.22
Unknown 3.76 1.80 5.72
Virulence 3.34 2.38 4.29
Alternative descriptions
Antibiotic resistance 3.99 2.91 5.08
Antigen 3.17 2.68 3.65
C. Nimmo et al. / EBioMedicine 55 (2020) 102747 7To establish which functional categories of genes were driving
changes in p over time, we examined p in the sequential isolates
from the 115 patients described above. Diversity increased across
multiple functional categories at the week 1 timepoint, before
decreasing but remaining more diverse than at baseline (Fig. 2). At
each timepoint different genes were responsible for the changes in
diversity seen (Table 5). The changes in mean p were seen at month
six are likely influenced by the small number of patients remaining
culture positive (11 patients). However there was a notable increase
in antibiotic resistance gene p at this timepoint, driven by hetRAVs in
Rv0678, a gene responsible for bedaquiline and clofazimineFig. 2. Change in mean nucleotide diversity (p) over time according to gene functional cat
Table 5
Genes with greatest increase in nucleotide div
timepoints.
Order Baseline!Week 1 Baseline
Gene Dp (£ 106) Gene
1 Rv1319c 62.7 accE5
2 Rv2319c 58.4 Rv1765c
3 Rv3424c 55.7 Rv2876
4 Rv0219 54.3 cfp6
5 Rv1083 53.8 Rv1498c
6 Rv1435c 51.6 cysA2
7 moaD1 48.8 mmpS4
8 mscL 44.1 parE1
9 Rv0634A 44.1 serB1
10 Rv0579 36.8 Rv3412resistance, and which occurred exclusively in patients who were
treated with bedaquiline and subsequently acquired clinical resis-
tance.3.6. Heteroresistance
We then assessed the prevalence of heteroresistance in isolates
with a minimum coverage depth of 55x that were not mixed infec-
tions. There were 399 baseline isolates included in this analysis, with
genetic resistance (presence of 1 heterozygous or fixed RAV) most
frequently identified in baseline isolates for rifampicin (77.1%) and
high-level isoniazid resistance (katG RAVs, 60.4%) as shown in Fig. 3a
in keeping with the sampling strategy for this study. Genetic resis-
tance conferred only by hetRAVs was proportionately most common
for bedaquiline, where the majority (60.0%, 6/10) of isolates con-
tained only heterozygous RAVs, and fluoroquinolones (12.7%, 9/62)
as shown in Fig. 3b. Examining all baseline hetRAVs (including where
multiple hetRAVs occurred in one isolate or where they were com-
bined with fixed RAVs), allele frequencies varied from the limit of
detection (7% at the minimum coverage of 55x, or 3% at coverage of
150x) to our nominated cut-off for fixation of 95% (Fig. 3c).
Where longitudinal sampling was available, the majority of
patients with resistance conferred by hetRAVs had either one resis-
tance mutation reaching fixation (9/20, 45%) or heteroresistance per-
sisting with at least one hetRAV (8/20, 40%) (Table 6, full index of all
hetRAVs in Supplementary Table 5). In three cases (15%) hetRAVs dis-
appeared altogether: one Rv0678 M146T mutation at 2.0% frequency
(associated with bedaquiline resistance), one rpoB S450L mutation ategories (solid icons). Two additional redundant categories are also plotted (bold text).
ersity (p) (expressed at £ 106) between
!Month 2 Baseline!Month 6
Dp (£ 106) Gene Dp (£ 106)
263.2 Rv0678 302.7
117.1 cysA2 136.3
111.5 Rv3612c 113.4
105.9 Rv2980 124.9
73.4 Rv3655c 123.6
72.3 Rv0100 119.6
70.8 Rv1948c 118.1
69.3 Rv2081c 92.0
57.8 Rv1134 89.3
55.3 Rv1000c 80.9
Fig. 3. (a) Number of baseline isolates with genetic resistance (i.e. containing any RAV) by drug, (b) percentage of baseline isolates with hetRAVs only amongst all RAVs and (c) base-
line allele frequency of all hetRAVs by drug, with lines showing median and interquartile range. Some isolates had >1 hetRAV.
8 C. Nimmo et al. / EBioMedicine 55 (2020) 1027479.1% frequency (rifampicin resistance) and one embB D328Y mutation
at 43.9% frequency (ethambutol resistance). In the five cases of rifam-
picin heteroresistance that became fixed or persisted, all patients
actually had two separate hetRAVs, all of which displayed dynamics
consistent with clonal interference of two resistant subpopulations
(Fig. 4a-e). Rifampicin had already been stopped in all five patients
following diagnosis of MDR-TB. Clonal interference was also seen in
both patients with fluoroquinolone heteroresistance (Fig. 4f-g) and
one of the patients with bedaquiline/clofazimine heteroresistance
(Fig. 4h), and all of these patients were still treated with the respec-
tive drugs. All pyrazinamide heteroresistance was caused by T153fs
mutations at high frequency, that were at or close to the arbitrary
cut-off of 95% for fixation.
3.7. Predicting emergent resistance
Emergent resistance in this cohort was rare, with only 9/286
(3.1%) of patients from cohorts where follow-up samples were rou-
tinely collected (studies one to four in Table 1) identified as acquiring
RAVs after exclusion of mixed infections and reinfections. Among the
77 patients with DS-TB one patient acquired a rifampicin RAV when
they relapsed at month 12, having initially culture converted at week
3, and one patient acquired an isoniazid RAV. Additionally, one
patient acquired a fluoroquinolone RAV, and six patients acquired
bedaquiline and clofazimine cross-resistance RAVs, one of whom also
acquired delamanid RAVs (Table 7). All new RAVs occurred in the
presence of treatment with the drug. All bedaquiline resistance was
conferred by RAVs in the efflux pump repressor gene Rv0678, withTable 6
Resistance patterns in longitudinal isolates from patients with re
ated variants (hetRAVs) at baseline. Numbers refer to patients.
Drug Patients with he
Total number RAV (s) become fix
Rifampicin 6 4 (66.7%)
Isoniazid 1 
Pyrazinamide 6 3 (50.0%)
Ethambutol 1 
Fluoroquinolones 2 1 (50.0%)
Second line Injectables 1 
Bedaquiline 3 1 (33.3%)no RAVs identified in the other resistance-associated genes atpE or
pepQ, which have been more frequently associated with resistance
in vitro or murine model studies [50,51].
To establish if emergence of genetic resistance could be predicted
by presence of low-frequency (1%) variants in preceding isolates,
we performed deep sequencing of resistance-associated genes (Sup-
plementary Table 1) with minimum and mean coverage of 2897x and
4072x respectively for seven of the nine patients with emergent
resistance and sufficient surplus DNA after standard WGS. Deep
sequencing revealed large numbers of low-frequency variants. For
example, the mean number of Rv0678 variants called was 66 over all
baseline isolates. Despite this, none of the emergent RAVs described
in Table 7 were identified in the preceding deep-sequenced isolates
and no phenotypic resistance was identified to any drug tested prior
to the emergence of a RAV on WGS, with the exception of participant
P3524 where three of five additional bedaquiline/clofazimine RAVs
that appeared at month six were present at frequencies around 1% in
the month 2 isolate. The month 2 isolate was phenotypically beda-
quiline and clofazimine resistant but also had bedaquiline RAVs at
>5% frequency. Further use of deep sequencing to identify low-fre-
quency variants will require a system validated to detect a range of
allele mixtures.
4. Discussion
In this study we have analysed within-host diversity of Mtb iso-
lates at the whole genome level, across gene classes and at specific
resistance-associated sites in several South African TB cohorts. Asistance conferred only by heterozygous resistance-associ-
tRAV presence in further isolate (s) (%)
ed RAV (s) remain heterozygous RAV (s) disappear
1 (16.7%) 1 (16.7%)
1 (100.0%) 
3 (50.0%) 
 1 (100.0%)
1 (50.0%) 
1 (100.0%) 
1 (33.3%) 1 (33.3%)
Fig. 4. Allele frequency graphs for patients with evidence of clonal interference in rpoB (a-e), gyrAB (f-g) and Rv0678 (h). Boxes indicate drugs included in the patient's treatment
regimen for which RAVs were present.
C. Nimmo et al. / EBioMedicine 55 (2020) 102747 9particular strength of this study is that all cohorts were prospective,
reducing the potential for bias in patient selection and by limiting the
number of subculturing steps prior to and following isolate storage.
The 6% rate of mixed infection that we identified is not as high as
the 1020% that has been reported in other studies in high-burdensettings [9,52], especially considering that WGS offers additional sen-
sitivity to detect mixed infections compared to previous technologies.
This may be because time to treatment initiation has decreased with
health systems changes, including introduction of the Xpert MTB/RIF
rapid diagnostic [53,54]. We did not identify any factors associated
Table 7
Emergent RAVs occurring while on treatment in patients who were previously wild-type in the context of single
strain infections. The month of RAV emergence as identified by WGS is shown and the frequency at this time, fol-
lowed by results of retrospective targeted deep sequencing of any isolates preceding RAV emergence onWGS. Dashes
indicate sequencing data not available for these isolates. *this patient was culture negative after six months’ treat-
ment for isoniazid monoresistant TB, but relapsed at month 12 with new rifampicin resistance.
Patient ID Drug Mutation Month of
emergence
Frequency at
emergence (WGS)
Frequency in retrospective
deep sequencing of isolate
preceding emergence
R0075 Rifampicin rpoB D435V 12* 83.3% absent
rpoB S450L 12* 17.2% absent
K0064 Isoniazid katGW328stop 0.25 5.9% 
P0064 Fluoroquinolones gyrA D94N 2 47.6% absent
K0061 Bedaquiline Rv0678 G138stop 0.25 4.5% 
P0082 Bedaquiline Rv0678 C46fs 5 92.6% absent
Rv0678 D47fs 4 55.6% absent
P0200 Bedaquiline Rv0678 D47fs 6 95.3% absent
P3505 Bedaquiline Rv0678 G147fs 6 94.5% absent
P3524 Bedaquiline Rv0678 Q22P 2 85.1% absent
Rv0678 D47fs 2 45.2% absent
Rv0678 A57E 6 10.6% 0.55%
Rv0678 R72T 6 9.2% absent
Rv0678 D88fs 6 12.0% absent
Rv0678 D88A 6 13.0% absent
Rv0678 G121R 6 6.0% 1.09%
Rv0678 L122P 6 7.4% 0.94%
Delamanid fbiC A487fs 6 24.7% absent
fbiC S534stop 6 11.9% absent
K0084 Bedaquiline Rv0678 V1A 6 60.0% absent
Rv0678 G37fs 6 11.9% absent
Rv0678 R89W 6 12.5% absent
10 C. Nimmo et al. / EBioMedicine 55 (2020) 102747with risk of mixed infection and contrary to previous studies did not
detect worse outcomes in patients with mixed infection, although we
compared six-month rather than end of treatment outcome and our
studies were heavily weighted for patients with DR-TB.
We sought to determine if technical factors such as subculturing in
liquid or solid media and isolate contamination could affect within-
host genetic diversity, and reassuringly none had a measurable effect.
While subculturing has been shown to lead to a loss in genetic diver-
sity, we limited subculturing to a single event, tried to transfer the
maximum volume of liquid culture possible or scrape all colonies from
solid plates. To prevent cross-mapping of contaminating reads artefac-
tually inflating within-host genetic diversity, we used sequence read
mapping software that allows stringent read-identity parameters to be
set which appeared effective on this dataset.
We expected diversity to be related to bacterial load in the origi-
nal patient sample but the absence of a correlation with smear posi-
tivity or TTP may be because these are not ideal measures of true
within-patient bacterial load, being inherently limited by the sto-
chasticity of sputum sampling and potential culture-induced bias.
Conversely other factors such as drug penetration or immune control
may be more important drivers of within-host genetic diversity than
bacterial population size. Supporting this, we did find greater genetic
diversity in patients with cavitary disease which may lead to spatially
separated bacterial subpopulations, likely exposed to a different
microenvironment for example in respect to drug concentrations
(Table 2). We also observed higher within-host genetic diversity in
patients who were HIV positive but not taking ART suggesting an
effect of immune constitution not captured by CD4 count.Mtb lineage
2 was correlated with greater diversity than lineage 4, supportive of
the proposed higher mutation rate in lineage 2 [55,56]. DS and MDR-
TB infections had similar genetic diversity, while pre-XDR/XDR were
less diverse and may represent the likely fitness costs of these addi-
tional mutations [57] (Table 2).
Overall, clinical outcomes were excellent with similar six-month
outcomes in DS and MDR-TB, backing up recent promising observa-
tional reports from MDR-TB programmes [58], although six-month
outcomes may not fully translate into end of treatment outcomes [59].While mixed infections have previously been reported to be associated
with poor end of treatment outcomes [5,6], in this study baseline
nucleotide diversity (p) at the point of initiating or undergoing a major
change in treatment regimen in single strain infection was not associ-
ated with six-month outcome (Table 3). Although we did not identify
worse outcomes in patients with mixed infection (which may be as
numbers were small), it suggests that the association between mixed
infection and poor outcomes reported elsewhere [5,6] is mediated by
a process independent of genomic diversity.
There was a significant increase in overall genomic p at weeks
12, which then reduced back to similar levels to baseline through-
out the rest of treatment (Fig. 1). There was no evidence of a decrease
from baseline in p during the later stages of treatment, although the
number of patients who were culture positive at later timepoints was
small, and inevitably successfully treated patients become culture
negative within the first weeks of treatment. The initial increase in
diversity was driven by increases in p of multiple different gene func-
tional categories (Fig. 2). While diversity appeared to increase again
at month six, numbers were small at this timepoint. As shown previ-
ously, we observed no enrichment of T cell antigens or antibiotic
resistance genes [14], except for the increase in diversity in antibiotic
resistance genes at month six driven by hetRAVs in Rv0678 among
patients who had acquired bedaquiline resistance.
Frequency of genetic heteroresistance varied considerably by drug
and was most common for bedaquiline and fluoroquinolones and
rare for isoniazid and rifampicin in line with previous descriptions
[44] (Fig. 3b). In contrast to other drugs, pyrazinamide heteroresist-
ance was largely caused by a single T153fs mutation at >90% fre-
quency that did not reach fixation, potentially as the associated
fitness cost [60] causes an evolutionary pressure to maintain the wild
type allele (although the fitness implications of pncA mutations
remain disputed [61]). Rv0678 bedaquiline/clofazimine RAVs often
persisted as heterozygous variants often throughout treatment, sug-
gesting there is an as yet undetermined underlying biological expla-
nation why they fail to reach fixation. A driving factor behind
heteroresistance to other antimycobacterial drugs may be the exis-
tence of Mtb subpopulations in lung cavities, where some drugs may
C. Nimmo et al. / EBioMedicine 55 (2020) 102747 11penetrate at subtherapeutic concentrations or not at all [20,62].
While this has not yet been conclusively demonstrated for bedaqui-
line, along with clofazimine it is predicted to exhibit poor penetration
into cavities [63].
While the majority of hetRAVs persisted or became fixed, some of
those at lower frequencies disappeared in sequential sampling. The
current allele frequency limit of detection of Xpert MTB/RIF for rifam-
picin heteroresistance by Xpert MTB/RIF is 2080% [27] and 5% for
fluoroquinolone heteroresistance by line probe assays [28]. It is
important that future rapid molecular diagnostics and whole genome
sequencing pipelines are designed to identify and quantify genetic
heteroresistance, as allele frequency may affect the clinical signifi-
cance of these mutations. Most patients with rifampicin and all with
fluoroquinolone heteroresistance demonstrated fluctuating hetRAV
frequencies consistent with clonal interference (Fig. 4), suggesting
the presence of more than one subclone co-existing for weeks or
months within a patient, rather than single dominant clone.
Emergent resistance during treatment was rare in this study com-
pared to reports from only a few years ago quoting acquired second-
line drug resistance in >25% of patients with MDR-TB during
treatment [64]. This could be due to the now widespread use of beda-
quiline and other bactericidal drugs which have been shown to
reduce acquisition of second line drug resistance [65] and other pro-
grammatic changes including introduction of rapid molecular diag-
nostics for resistance and the nine-month regimen in addition to the
rigorous exclusion of mixed and reinfection by WGS of all isolates.
Rv0678 variants conferring bedaquiline/clofazimine cross-resistance
accounted for the majority of emergent resistance mutations, which
is likely to reflect both the relative importance of these drugs to cur-
rent regimens and also that it may be comparatively easy for Mtb to
acquire resistance due to the large mutational target for bedaquiline/
clofazimine resistance with any mutation disrupting the function of
the Rv0678 gene removing repression of the MmpL5 efflux pump.
While there have been several reports of microheteroresistance
(RAVs with <5% allele frequency) RAVs pre-dating the emergence of
macroheteroresistance (RAVs with 595% allele frequency) or fixed
resistance, in this prospectively enrolled cohort we found a high
degree of noise with large numbers of very low-frequency variants
detected on retrospective deep sequencing of isolates collected pre-
ceding the emergence of resistance of WGS. This may reflect either
high turnover of variants that are rapidly selected against and/or
sequencing error, and effectively separating the two remains chal-
lenging without a gold standard to discriminate the two. SureSelect
RNA bait enrichment has previously been shown to not to bias popu-
lation structure of heterozygous alleles with frequency >1% [66], but
should be studied further inMtb using a culture and sequencing pipe-
line that has been formally validated with in vitro allele mixtures of
different frequencies covering the range of interest. However, as very
few of the emergent RAVs were identified even among the multiple
low-frequency variants that may represent standing variation or
sequencing error [2], it suggests that weekly or more frequent sam-
pling in addition to effective exclusion of sequencing error would be
required to identify low-frequency RAVs that were likely to be clini-
cally significant. This is in agreement with another study of treatment
failures that found that only variants at >19% frequency were likely
to become fixed [14] and that very low-frequency variants did not
affect outcome of patients with DS-TB [5].
Limitations of this study include that, as for the majority of studies
of Mtb, WGS was performed on cultured isolates that may not truly
represent the true within-host diversity. Sequencing directly from
sputum is now possible but had not been implemented on sufficient
scale to utilise during this study period. Not all cohorts collected sam-
ples at all timepoints, with week 1 data sourced from two cohorts and
week 2 data from one cohort. Some patients were already taking
treatment at the time of study entry, and although to be enrolled the
patient would have to still be culture positive and require addition of2 new drugs, it is possible that pre-treatment may have affected
genetic diversity. Additionally, we selected cohorts that primarily
recruited patients with DR-TB as these patients were expected to be
at higher risk of acquiring further drug resistance and have prolonged
culture positivity compared to patients with DS-TB. Therefore, while
the findings may be true for these cohorts which ultimately had good
treatment outcomes and relatively rare acquisition of further resis-
tance, they do not necessarily represent a true cross-section of
patients with TB in South Africa or elsewhere in the world.
In conclusion, in this prospective study of South African patients
starting TB treatment, most of whom had at least first line drug-resis-
tance, there was no association between within-host genetic diver-
sity and clinical outcome for patients infected with a single strain.
Studying within-host Mtb genetic diversity identifies changes in
genetic diversity during treatment and is a potential tool to investi-
gate the bacterial response to selective pressures. Further work is
required to delineate allele frequency thresholds for identification of
significant low-frequency RAVs, and frequent sampling may be
required to identify them. The emergence of bedaquiline/clofazimine
and delamanid resistance is concerning and highlights the need for
rigorous antimicrobial stewardship and resistance monitoring.
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